JUPITER NEUROSCIENCES Business Summary

Jupiter Neurosciences, Inc. (JUNS) operates a "dual-path" business model that integrates clinical-stage pharmaceutical development with a commercial consumer longevity segment. The company’s primary value driver is its proprietary JOTROL™ platform, a patented delivery system designed to enhance the bioavailability of resveratrol for treating neuroinflammation and central nervous system (CNS) disorders. Revenue is generated through two distinct streams: the commercial sale of its Nugevia™ consumer supplement line—which utilizes a subscription-based ecommerce model—and potential milestone payments or royalties from the licensing and global distribution of its pharmaceutical pipeline, currently headlined by a Phase 2a trial for Parkinson’s disease. In the competitive CNS landscape, Jupiter contends with major players such as Biogen, Eli Lilly, Biohaven, and Cassava Sciences. Unlike these competitors, which often focus on monoclonal antibodies or traditional small molecules, Jupiter positions itself as a specialist in bioavailability enhancement and neuroinflammation, leveraging its consumer-facing revenue to reduce the capital-intensive reliance on external financing typical of biotechnology peers. The company was founded by a multi-disciplinary team led by Christer Rosén, who serves as Chairman and CEO, bringing over three decades of international entrepreneurial experience. The executive leadership includes Chief Scientific Officer Dr. Marshall Hayward, a former executive at SmithKline Beecham and Effrx Pharmaceuticals with deep expertise in drug approvals, and Chief Financial Officer Saleem Elmasri, a CPA who manages the firm’s strategic capital facilities. The scientific foundation is anchored by co-founder Dr. Claes Wahlestedt, a renowned neuroscientist and professor at the University of Miami Miller School of Medicine, and President and CBO Alison D. Silva, who previously co-founded Synlogic. Notable financial backing includes a strategic $20 million financing agreement with Yorkville Advisors, while the company’s scientific advisory board features prominent researchers like Dr. Scott Turner. This leadership team combines high-level academic pedigree with commercial execution capabilities to bridge the gap between laboratory research and market-ready therapeutics.